^
Association details:
| Biomarker: | RB1 deletion |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | birinapant (IGM-9427) (IAP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
RB loss determines selective resistance and novel vulnerabilities in ER-positive breast cancer models
Published date:
06/09/2022
Excerpt:
The combination of AURK and WEE1 inhibitors, yields synergistic cell death selectively in RB-deleted ER+ breast cancer cells via apoptosis and yields profound disease control in vivo. Through unbiased efforts the XIAP/CIAP inhibitor birinapant was identified as a novel RB-selective agent. Birinapant further enhances the cytotoxic effect of chemotherapies and targeted therapies used in the treatment of ER+ breast cancer models selectively in the RB-deficient setting.
Secondary therapy:
Chemotherapy
DOI:
10.1038/s41388-022-02362-2
